Tag Archives: world

Oral cancer-causing HPV may spread through oral, genital routes

“HPV is the most common sexually transmitted disease in the world, and is a risk factor for several cancers, including cervical, vaginal, vulvar, oropharyngeal [throat/tonsil], anal, and penile cancer,” says Eduardo L. Franco, Professor and Director of the Division of Cancer Epidemiology at McGill University. “Understanding how HPV is transmitted is important because it will help us identify who is most at risk for HPV infection and how we can help them protect themselves and their partners,” adds Franco, who is also the Chairman of the Department of Oncology in the Faculty of Medicine. “Our work provides additional evidence that HPV is sexually transmitted to the oral tract through oral-oral and oral-genital contact.” Infection rates higher for male smokers A research team led by Franco looked at HPV infections in 222 men and their female partners and found that among men in the study, the prevalence of oral HPV was 7.2 percent…

Tumor-analysis technology enables speedier treatment decisions for bowel cancer patients

A novel medical-imaging technology, TexRAD, which analyses the texture of tumors, has been shown in trials to enable early diagnosis of those bowel-cancer patients not responding to the standard cancer therapy better than other available tumor markers. Furthermore, the TexRAD markers showed the ability to assess at an early stage the likelihood of survival, distinguishing patients who will have a good prognosis from those having poor prognosis. Dr Balaji Ganeshan, one of the Sussex academics whose research led to the development of the technology, said: “By using TexRAD to scan for subtle anomalies in a tumor’s texture, researchers have been able to spot more quickly when treatments are — or are not — working and adjust treatment accordingly. “And because TexRAD simply provides an additional layer of software analysis of the MRI and CT scans that already exist as part of routine clinical practice, it is non-invasive from the patient’s point of view and potentially cost-effective to the healthcare provider.” The technology is being evaluated in a number of research institutions and university hospitals around the world. …

Olaparib shows success in tumor response rate for patients with BRCA-related cancers

For the majority of patients in the study, olaparib was at least their third different cancer therapy. Based on the new data, the authors say olaparib warrants further investigation in phase III trials. The positive response in metastatic pancreatic cancer patients who had received an average of two prior rounds of chemotherapy is an especially noteworthy finding since therapeutic options for these patients are limited. …

How radiotherapy kills cancer cells

Dr Jason Greenwood from Queen’s Centre for Plasma Physics collaborated with academics from Italy and Spain on the work on electrons, which has been published in the international journal Science. Using some of the shortest laser pulses in the world, the researchers used strobe lighting to track the ultra-fast movement of the electrons within a nanometer-sized molecule of amino acid. The resulting oscillations — lasting for 4,300 attoseconds (billion-billionths of a second) — amount to the fastest process ever observed in a biological structure. …

New viral mutation made middle-aged adults more susceptible to last year’s flu

“We identified a mutation in recent H1N1 strains that allows viruses to avoid immune responses that are present in a large number of middle-aged adults,” said Scott Hensley, Ph.D., a member of Wistar’s Vaccine Center and an assistant professor in the Translational Tumor Immunology program of Wistar’s Cancer Center. Historically, children and the elderly are most susceptible to the severe effects of the influenza viruses, largely because they have weaker immune systems…

Adenocarcinoma: UK tops global league table for gullet cancer in men

Rates of SCC have remained fairly stable or have even fallen over the past few years, but those of adenocarcinoma have risen, particularly in high income countries. In 2012, esophageal cancer was the eighth most common cancer worldwide. The researchers used data from Cancer Incidence in Five Continents volume 10 to calculate age, sex, and country specific proportions of the two types of esophageal cancer. These figures were then applied to IARC global data on the number of new esophageal cancer cases in 2012 (GLOBOCAN 2012), and age-standardised rates calculated. …

Ebola highlights disparity of disease burden in developed vs. developing countries

“Our goal is to provide information about trends and patterns to bring to light what’s going on around the world so that funds can be allocated and policy developed as needed,” says Lindsay Boyers, medical student at Georgetown University, working in the lab or Robert Dellavalle, MD, PhD, MSPH investigator at the University of Colorado Cancer Center, associate professor of dermatology at the University of Colorado School of Medicine, and the paper’s senior author. The paper used data from the Global Burden of Disease Study, an ongoing project funded by the Bill and Melinda Gates Foundation to collect a billion data points describing the distribution of the world’s diseases. Of the 269 diseases in the GBD database, this study compares rates in developed versus developing countries of Ebola, malignant melanoma, basal and squamous cell carcinoma, decubitus ulcer, bacterial skin diseases, cellulitis, varicella (including chickenpox, congenital varicella infection, and herpes zoster), syphilis, measles, and dengue. Specifically, findings show that in 2010 the measles death rate was 197 times greater in developing countries than in developed countries, but this ratio was down from 345-to-1 in 1990. …

New cancer drug to begin trials in multiple myeloma patients

In a paper published today in the journal Cancer Cell, the researchers report how the drug, known as DTP3, kills myeloma cells in laboratory tests in human cells and mice, without causing any toxic side effects, which is the main problem with most other cancer drugs. The new drug works by stopping a key process that allows cancer cells to multiply…